Anthony Cheung
Fondatore presso ENGENE HOLDINGS INC.
Patrimonio netto: 904 254 $ in data 31/05/2024
Posizioni attive di Anthony Cheung
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ENGENE HOLDINGS INC. | Direttore Tecnico/Scientifico/R&S | 24/04/2023 | - |
| Fondatore | 24/04/2023 | - | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Direttore/Membro del Consiglio | - | - |
| Direttore Tecnico/Scientifico/R&S | 16/07/2018 | - | |
| Fondatore | - | - | |
| Amministratore Delegato | 25/10/2011 | 16/07/2018 | |
| Presidente | 25/10/2011 | 16/07/2018 | |
| Segretario Aziendale | 01/01/1999 | 25/05/2011 |
Storia della carriera di Anthony Cheung
Formazione di Anthony Cheung
| University of British Columbia | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Canada | 4 |
| Stati Uniti | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ENGENE HOLDINGS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Borsa valori
- Insiders
- Anthony Cheung
- Esperienza
